Article
Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.
Current oncology reports - 1 Jan 2016
Johnpulle Romany A N, Johnson Douglas B, Sosman Jeffrey A
Abstract excerpt
Patients with metastatic melanoma have historically had dismal outcomes. The last several years has seen the emergence of effective immune and targeted therapies for metastatic melanoma. Targeted therapies have primarily impacted the 40-50% of patients with BRAF(V600) mutated melanoma. The remainder of patients with advanced melanoma harbor a wide spectrum of mutations other than BRAF(V600) that are associated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.